

# ASH 2023

## 65th ASH Annual Meeting and Exposition

December 9–12, 2023  
San Diego, US



## TOP ABSTRACTS

To help navigate the exciting content being presented at the 65th ASH Annual Meeting and Exposition, we have provided recommendations for the top abstracts to look out for in acute myeloid leukemia (AML).

December 9–12, 2023

Early phase trials				
	<b>55</b> <a href="#">View</a>	Saturday, Dec 9 09:30–09:45	Selinexor in combination with venetoclax and azacitidine for newly diagnosed (ND) unfit acute myeloid leukemia (AML): a multicenter, open-label prospective study	Li Yang
	<b>56</b> <a href="#">View</a>	Saturday, Dec 9 09:45–10:00	Preliminary safety and efficacy of venetoclax and selinexor in combination with chemotherapy in pediatric and young adult patients with relapsed or refractory acute myeloid leukemia: Selclax	Sara Zarnegar-Lumley
	<b>57</b> <a href="#">View</a>	Saturday, Dec 9 10:00–10:15	A first-in-human phase 1 study of the menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed/refractory acute leukemia harboring <i>KMT2A</i> or <i>NPM1</i> alterations	Elias Jabbour
	<b>58</b> <a href="#">View</a>	Saturday, Dec 9 10:15–10:30	Early results of the phase I/II study investigating the all-oral combination of the menin inhibitor revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax in acute myeloid leukemia (SAVE)	Ghayas C. Issa
	<b>59</b> <a href="#">View</a>	Saturday, Dec 9 10:30–10:45	TIM-3 inhibitor sabatolimab for patients with acute myeloid leukemia (AML) with measurable residual disease (MRD) detected after allogeneic stem cell transplantation (AlloSCT): Preliminary findings from the phase Ib/II STIMULUS-AML2 study	Robert Zeiser
	<b>60</b> <a href="#">View</a>	Saturday, Dec 9 10:45–11:00	Overcoming venetoclax (Ven) resistance through glutamine (Gln) depletion: Final analysis of the phase 1 trial of Ven and pegcrisantaspace (PegC) combination in relapsed and refractory (R/R) acute myeloid leukemia (AML)	Yuchen Liu
	<b>158</b> <a href="#">View</a>	Saturday, Dec 9 14:15–14:30	Phase I/II study of quizartinib, venetoclax, and decitabine triple combination in FLT3-ITD mutated AML	Musa Yilmaz
	<b>159</b> <a href="#">View</a>	Saturday, Dec 9 14:30–14:45	Final results of the phase Ib/II study evaluating enasidenib in combination with venetoclax in patients with IDH2-mutated relapsed/refractory myeloid malignancies	Guillaume Richard-Carpentier
	<b>160</b> <a href="#">View</a>	Saturday, Dec 9 14:45–15:00	Venetoclax plus high-dose cytarabine and mitoxantrone (HAM-Ven) as salvage treatment for relapsed/refractory AML: updated results of the phase-I/II SAL Relax trial	Leo Ruhnke

	<b>162</b> <a href="#">View</a>	Saturday, Dec 9 15:15–15:30	Tuspetinib myeloid kinase inhibitor safety and efficacy as monotherapy and combined with venetoclax in phase 1/2 trial of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML)	Naval Daver
	<b>218</b> <a href="#">View</a>	Saturday, Dec 9 14:15–14:30	Naturally selected CD7-targeted chimeric antigen receptor (CAR)-T cell therapy for refractory/relapsed acute myeloid leukemia: phase I clinical trial	Peihua Lu
	<b>230</b> <a href="#">View</a>	Saturday, Dec 9 14:15–14:30	Optimizing outcomes with myeloablative conditioning in older patients: Efficacy and safety of precision engineered Orca-T in patients > 55 years old with hematologic malignancies	Caspian H. Oliai
	<b>470</b> <a href="#">View</a>	Sunday, Dec 10 09:45–10:00	Final results from phase 1 study of briquilimab, an anti-CD117 monoclonal antibody, in combination with low dose irradiation and fludarabine conditioning, shows durable remissions in older adults with acute myeloid leukemia in complete remission and myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation	Arpita Gandhi
	<b>471</b> <a href="#">View</a>	Sunday, Dec 10 10:00–10:15	Mega-dose decitabine intensified regimen is more effective at eliminating pre-HSCT measurable residual disease compared to the Bu/Cy regimen: a multicenter prospective phase II study	Hao Zheng
	<b>474</b> <a href="#">View</a>	Sunday, Dec 10 10:45–11:00	The modified melphalan-cladribine-busulfan-cyclophosphamide (MCBC) conditioning regimen improved relapse-free survival after allo-HSCT in refractory/relapsed AML	Xiaoyu Zhang
	<b>773</b> <a href="#">View</a>	Monday, Dec 11 11:30–11:45	Safety and efficacy of Orca-Q with haploidentical donors for the treatment of advanced hematologic malignancies without the use of post-transplant cyclophosphamide	Samer A. Srouf
	<b>771</b> <a href="#">View</a>	Monday, Dec 11 11:00–11:15	CD33 CAR T-cells (CD33CART) for children and young adults with relapsed/refractory AML: dose-escalation results from a phase I/II multicenter trial	Nirali N. Shah
	<b>830</b> <a href="#">View</a>	Monday, Dec 11 15:00–15:15	MRD directed treatment intensification with either FLAG-Ida or DA-Cladribine improves survival in older AML patients: results from the NCRI AML18 randomised trial	Nigel H. Russell
	<b>832</b> <a href="#">View</a>	Monday, Dec 11 15:30–15:45	Quantum-First trial: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-specific measurable residual disease (MRD) clearance assessed through induction (IND) and consolidation (CONS) is associated with improved overall survival (OS) in newly diagnosed (nd) FLT3-ITD+ AML patients (pts)	Alexander Perl

	<b>833</b> <a href="#">View</a>	Monday, Dec 11 15:45–16:00	A phase 2 study of the fully oral combination of ASTX727 (decitabine/cedazuridine) plus venetoclax for older and/or unfit patients with acute myeloid leukemia	Tapan M. Kadia
	<b>834</b> <a href="#">View</a>	Monday, Dec 11 16:00–16:15	Venetoclax plus azacitidine, low dose cytarabine, aclarubicin and G-CSF (VA-CAG Regimen) for newly diagnosed young patients with acute myeloid leukemia: a prospective, multicenter, single-arm phase 2 clinical trial	Xiaoping Li
	<b>968</b> <a href="#">View</a>	Monday, Dec 11 16:45–17:00	Phase Ib/2 study of oral decitabine/cedazuridine (ASTX727) and venetoclax in combination with the targeted mutant IDH1 inhibitor ivosidenib or the targeted mutant IDH2 inhibitor enasidenib: 2023 update	Himachandana Atluri
	<b>969</b> <a href="#">View</a>	Monday, Dec 11 17:00–17:15	Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: updated results of a phase II trial	Xiaohui Suo
	<b>970</b> <a href="#">View</a>	Monday, Dec 11 17:15–17:30	Comparing the efficacy and safety of venetoclax combined with decitabine versus conventional chemotherapy as induction therapy for young adults with newly diagnosed acute myeloid leukemia - interim analysis of a multicenter, randomized, phase 2b trial	Jing Lu
	<b>974</b> <a href="#">View</a>	Monday, Dec 11 16:45–17:00	The FLT3-like gene expression signature predicts response to quizartinib in wild-type FLT3 acute myeloid leukemia: an analysis of the Pethema Quiwi trial	Adrian Mosquera Orgueira
	<b>1040</b> <a href="#">View</a>	Monday, Dec 11 16:45–17:00	Infusion of UM171-expanded cord blood led to excellent survival in patients with high-risk leukemias: results from two independent phase II studies	Filippo Milano
	<b>2906</b> <a href="#">View</a>	Sunday, Dec 10 18:00–20:00	Pivekimab sunirine (PVEK, IMG632), a CD123-targeting antibody-drug conjugate, in combination with azacitidine and venetoclax in patients with newly diagnosed acute myeloid leukemia	Naval Daver
	<b>LBA-5</b> <a href="#">View</a>	Tuesday, Dec 12 09:00–10:30	Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemia: topline efficacy and safety results from the Pivotal Augment-101 phase 2 study	Ibrahim Aldoss

## Late phase trials

	<b>263</b> <a href="#">View</a>	Saturday, Dec 9 15:00–15:15	Alignment of later phase clinical trial eligibility criteria with drug safety in acute leukemia: minimizing unnecessary patient risk and exclusion	Thomas P. Walsh
	<b>469</b> <a href="#">View</a>	Sunday, Dec 10 09:30–09:45	I-Apamistamab-led allogeneic hematopoietic cell transplant significantly improves overall survival in patients with TP53 mutated R/R AML	Hannah Choe
	<b>594</b> <a href="#">View</a>	Sunday, Dec 10 17:45–18:00	Older adults with acute myeloid leukemia (AML) experience improvement in health-related quality of life (HRQoL) scores with intensive therapy: prospective study from ECOG-ACRIN (EA) E2906 phase 3 trial	James M. Foran
	<b>730</b> <a href="#">View</a>	Monday, Dec 11 11:15–11:30	Outcomes for children with high risk acute myeloid leukemia on the MyeChild 01 international phase III clinical trial	Andrew Moore
	<b>732</b> <a href="#">View</a>	Monday, Dec 11 11:45–12:00	Preferential efficacy of remission maintenance with HDC/IL-2 in age groups of patients with chemoresponsive or normal karyotype AML	Kristoffer Hellstrand
	<b>829</b> <a href="#">View</a>	Monday, Dec 11 14:45–15:00	Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed AML based on the peripheral blast clearance rate: first result of the multicenter, randomized, phase 3 trial (RJ-AML 2016)	Yunxiang Zhang
	<b>918</b> <a href="#">View</a>	Monday, Dec 11 16:00–16:15	Patient-reported outcomes in acute myeloid leukemia patients with <i>FLT3</i> -ITD mutation receiving quizartinib vs. standard chemotherapy: results from the Quantum-First trial	Esther Natalie Oliva
	<b>972</b> <a href="#">View</a>	Monday, Dec 11 17:45–18:00	Quantum-First: Safety by treatment phase and by age in newly diagnosed (nd) patients (pts) with FMS-like tyrosine kinase 3–internal tandem duplication ( <i>FLT3</i> -ITD) positive acute myeloid leukemia (AML)	Harry P. Erba
	<b>973</b> <a href="#">View</a>	Monday, Dec 11 16:30–16:45	Post-hoc analysis of measurable residual disease from BMT-CTN 1506/Morpho: FLT3-ITD variant allele frequency and survival are highly correlated	Mark J. Levis
	<b>1041</b> <a href="#">View</a>	Monday, Dec 11 17:00–17:15	Haploidentical hematopoietic cell transplantation combined with an unrelated cord blood unit for adult acute myeloid leukemia results in improved survival compared to haploidentical hematopoietic cell transplantation: results of a multicenter, randomized, phase III trial	Biqi Zhou

	<b>1495</b> <a href="#">View</a>	Saturday, Dec 9 17:30–19:30	Decider-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid (ATRA) or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy	Michael Lübbert
	<b>1582</b> <a href="#">View</a>	Saturday, Dec 9 17:30–19:30	Clonal dynamics of gene mutations during oral azacitidine maintenance therapy in patients with acute myeloid leukemia (AML): outcomes from the QUAZAR AML-001 trial	Daniel Lopes De Menezes
	<b>4254</b> <a href="#">View</a>	Monday, Dec 11 18:00–20:00	Kinetics of complete remission (CR) and CR duration and its impact on overall survival (OS) and event-free survival (EFS) in Quantum-First	Pau Montesinos
	<b>5097</b> <a href="#">View</a>	Monday, Dec 11 18:00–20:00	The UK Impact Transplant Trials Network: An effective national strategy to accelerate the delivery of randomized trials in stem cell transplantation	Charles Craddock

### Real-world, registry, and observational studies

	<b>62</b> <a href="#">View</a>	Saturday, Dec 9 09:45–10:00	Machine learning provides individualized prediction of outcomes after first complete remission in adult AML patients - results from the Harmony Platform	Alberto Hernández Sánchez
	<b>161</b> <a href="#">View</a>	Saturday, Dec 9 15:00–15:15	Acute myeloid leukemia patients who stopped venetoclax or/and azacytidine for other reasons than progression have a prolonged treatment free remission and overall survival: a Filo study	Sylvain Garciaz
	<b>236</b> <a href="#">View</a>	Saturday, Dec 9 14:15–14:30	MMF is associated with worse OS in CMV seropositive AML patients undergoing MUD HCT with calcineurin-inhibitor-based GvHD prophylaxis	Rohtesh S. Mehta
	<b>261</b> <a href="#">View</a>	Saturday, Dec 9 14:30–14:45	Age-related differences in utilization of allogeneic HCT for acute myeloid leukemia in California: results of a population-based, novel linked dataset	Christa L Meyer
	<b>421</b> <a href="#">View</a>	Sunday, Dec 10 09:30–09:45	Molecular relapse after first-line intensive therapy in patients with core-binding factor and NPM1-mutated acute myeloid leukemia – a Filo study	Corentin Orvain
	<b>425</b> <a href="#">View</a>	Sunday, Dec 10 10:30–10:45	The benefit of allogeneic transplant in 1st complete remission in <i>NPM1</i> Mutated AML with or without <i>FLT3</i> ITD is restricted to those testing MRD positive after induction – an analysis of the UK NCRI AML17 and AML19 studies	Jad Othman

	<b>550</b> <a href="#">View</a>	Sunday, Dec 10 12:45–13:00	Intensive chemotherapy (IC) followed by oral azacitidine (AZA) maintenance versus venetoclax (VEN) plus AZA for patients (pts) with acute myeloid leukemia (AML): retrospective analysis of an Electronic Medical Record (EMR) database in the United States	Alice Mims
	<b>592</b> <a href="#">View</a>	Sunday, Dec 10 17:15–17:30	Comparable survival of treatment Naïve <i>TP53</i> mutated acute myeloid leukemia treated with hypomethylating agent compared to hypomethylating agent plus venetoclax based therapy	Talha Badar
	<b>657</b> <a href="#">View</a>	Sunday, Dec 10 17:00–17:15	Pre-transplant somatic co-occurring mutations (by next generation sequencing) in acute myeloid leukemia: Frequency and impact on clinical outcomes after allogeneic hematopoietic cell transplantation - a large study on behalf of the EBMT Acute Leukemia Working Party	Ali Bazarbachi
	<b>658</b> <a href="#">View</a>	Sunday, Dec 10 17:15–17:30	The impact of <i>DNMT3A</i> mutation on survival of AML patients receiving allogeneic hematopoietic cell transplantation in first remission depends on the karyotype and co-occurring mutations: on behalf of the EBMT Acute Leukemia Working Party	Iman Abou Dalle
	<b>659</b> <a href="#">View</a>	Sunday, Dec 10 17:30–17:45	Comparative study for haplo, MSD and MUD allo-hcts for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation	Yishan Ye
	<b>896</b> <a href="#">View</a>	Monday, Dec 11 15:00–15:15	How much have post-transplant outcomes improved since 2000 for older patients with acute myeloid leukemia? A study from the EBMT Acute Leukemia Working Party	Ali Bazarbachi
	<b>958</b> <a href="#">View</a>	Monday, Dec 11 17:15–17:30	The shifting prognosis of <i>FLT3</i> mutations in acute myeloid leukemia in the era of targeted therapy: A real-world study using large-scale electronic health record data	Matthew Schwede
	<b>967</b> <a href="#">View</a>	Monday, Dec 11 16:30–16:45	Current results of intensive therapy in younger adults with acute myeloid leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 study on behalf of the Filo, ALFA, and SFGM-TC study groups	Hunault-Berger Mathilde
	<b>971</b> <a href="#">View</a>	Monday, Dec 11 17:30–17:45	A comparison of acute myeloid leukemia (AML) regimens: Hypomethylating agents combined with ivosidenib or venetoclax in newly diagnosed patients with IDH1 mutations: a real-world evidence study	B. Douglas Smith

	<b>975</b> <a href="#">View</a>	Monday, Dec 11 17:00–17:15	Fms-like tyrosine kinase 3 ligand kinetic profile is the strongest factor predicting refractoriness after induction and event-free survival in adults with AML: a Filo prospective multicentric study	Pierre Peterlin
	<b>977</b> <a href="#">View</a>	Monday, Dec 11 17:30–17:45	Molecular ontogeny in AML is both prognostic and predictive in patients treated with hypomethylating agents plus venetoclax	Shai Shimony
	<b>1043</b> <a href="#">View</a>	Monday, Dec 11 17:30–17:45	Comparing older matched related to younger matched unrelated donors in acute myeloid leukemia in remission using post-transplant cyclophosphamide	Simona Piemontese
	<b>1049</b> <a href="#">View</a>	Monday, Dec 11 17:30–17:45	Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with relapsed/refractory secondary versus <i>de novo</i> AML: a study from the ALWP/EBMT	Arnon Nagler

### Classification systems

	<b>61</b> <a href="#">View</a>	Saturday, Dec 9 09:30–09:45	Modification of the ELN classification 2022 refines risk assessment in MDS/AML patients	Gregor Hoermann
	<b>819</b> <a href="#">View</a>	Monday, Dec 11 15:15–15:30	Unraveling the impact of 2022 classifications on secondary acute myeloid leukemia: assessing the true qualification power of diagnostic qualifiers	Enrico Attardi
	<b>1566</b> <a href="#">View</a>	Saturday, Dec 9 17:30–19:30	Advances in acute myeloid leukemia classification: A comparative analysis of Who-HAEM4R, Who-HAEM5, and International Consensus Classification	Xue Chen

### Older patients

	<b>376</b> <a href="#">View</a>	Saturday, Dec 9 16:45–17:00	Frail and pre-frail older adults with acute myeloid leukemia have inferior survival due to higher rates of disease-related deaths	Ashley D. Hadjis
	<b>374</b> <a href="#">View</a>	Saturday, Dec 9 16:15–16:30	Individual-level social determinants of health (SDOH) measures and treatment complications in acute leukemia	Eshana Shah
	<b>955</b> <a href="#">View</a>	Monday, Dec 11 16:30–16:45	Evolving racial/ethnic disparities in AML survival in the novel therapy era: Real-world evidence of improved survival in older patients with the largest improvement in non-Hispanic Black patients	Xin Wang

Biomarkers				
	<b>63</b> <a href="#">View</a>	Saturday, Dec 9 10:00–10:15	Genomic Characterization of Acute Myeloid Leukemia with Aberrations of Chromosome 7: A Multinational Cohort of 523 Patients	Adriane Halik
	<b>424</b> <a href="#">View</a>	Sunday, Dec 10 10:15–10:30	Measurable residual <i>IDH2</i> before allogeneic transplant for acute myeloid leukemia	Gege Gui
	<b>721</b> <a href="#">View</a>	Monday, Dec 11 10:30–10:45	Secondary-type mutations do not impact the favorable outcome of <i>NPM1</i> -mutated acute myeloid leukemia patients – results from a large cohort of intensively treated patients	Marius Bill
	<b>723</b> <a href="#">View</a>	Monday, Dec 11 11:00–11:15	Mutational and cytogenetic dynamics at diagnosis and relapse in acute myeloid leukemia: influence of intensity and type of treatment	Alex Bataller
	<b>817</b> <a href="#">View</a>	Monday, Dec 11 14:45–15:00	Prognostic impact of clonality of myelodysplasia-related gene mutations in AML	Rabea Mecklenbrauck
	<b>818</b> <a href="#">View</a>	Monday, Dec 11 15:00–15:15	Influence of bone marrow blast enumeration and co-occurring myelodysplasia related gene mutations in <i>NPM1</i> -mutated myeloid malignancies	Curtis A. Lachowicz
	<b>821</b> <a href="#">View</a>	Monday, Dec 11 15:45–16:00	Molecular and cytogenetic characteristics of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in patients exposed to chemotherapy (CT) and/or radiation (XRT)	Pinkal Desai
	<b>837</b> <a href="#">View</a>	Monday, Dec 11 15:15–15:30	Genomic profiles and associated survival prognosticators in Black patients with acute myeloid leukemia	Andrew Stiff
	<b>957</b> <a href="#">View</a>	Monday, Dec 11 17:00–17:15	<i>NPM1</i> -mutated myeloid neoplasms: Updated outcomes with high-intensive chemotherapy regardless of the blast percentage	Georgina Gener-Ricos
	<b>959</b> <a href="#">View</a>	Monday, Dec 11 17:30–17:45	Clinical and prognostic implications of <i>WT1</i> mutations in <i>de novo</i> and relapsed acute myeloid leukemia	Himachandana Atluri
	<b>2939</b> <a href="#">View</a>	Sunday, Dec 10 18:00–20:00	Interaction between presenting features, co-occurring mutations, MRD and induction treatment influences outcome in adults with <i>NPM1</i> mutated AML – an analysis of 1357 patients in the UK NCRI AML17 and AML19 studies	Jad Othman
	<b>LBA-6</b> <a href="#">View</a>	Tuesday, Dec 12 09:00–10:30	ERG Is a new predisposition gene for bone marrow failure and hematological malignancy	Hamish S. Scott

## Translational research

	<b>217</b> <a href="#">View</a>	Saturday, Dec 9 14:00–14:15	Cytokine release syndrome results in reduced AML killing by CD123 CAR T cells	Anand S. Bhagwat
★	<b>466</b> <a href="#">View</a>	Sunday, Dec 10 10:15–10:30	WU-NK-101 (W-NK), a memory-like (ML) NK cell, intrinsically overcomes factors restricting adoptive cell therapy (ACT) in acute myeloid leukemia (AML)	Sergio Rutella
	<b>978</b> <a href="#">View</a>	Monday, Dec 11 17:45–18:00	Acute myeloid leukemia differentiation state and genotype influence anti-apoptotic protein expression, venetoclax sensitivity, and survival in AML	Curtis A. Lachowicz
	<b>165</b> <a href="#">View</a>	Saturday, Dec 9 14:30–14:45	Optimizing FLT3 inhibitor use in adult acute myeloid leukemia with FLT3 mutations using proteomics	Eduardo Sabino Magalhaes
	<b>290</b> <a href="#">View</a>	Saturday, Dec 9 16:15–16:30	CLEC2A is a novel AML-restricted immunotherapeutic target enriched in <i>KMT2A</i> -rearranged acute myeloid leukemia	Danielle Kirkey
	<b>423</b> <a href="#">View</a>	Sunday, Dec 10 10:00–10:15	Venetoclax has potent efficacy in <i>NPM1</i> mutated AML with acquired resistance associated with either perturbed pro-survival signalling or <i>NPM1</i> wild-type populations	Chong Chyn Chua
★	<b>1577</b> <a href="#">View</a>	Saturday, Dec 9 17:30–19:30	Pre-transplant measurable residual disease (MRD) detection of <i>KMT2A</i> -rearranged acute myeloid leukemia is strongly associated with inferior post-transplant outcome	Sun Loo
	<b>1588</b> <a href="#">View</a>	Saturday, Dec 9 17:30–19:30	Leukemic stem cells (LSCs) as peri-transplant MRD assessment in AML patients undergoing allogeneic stem cell transplantation in CR	Evgeny Klyuchnikov
	<b>1591</b> <a href="#">View</a>	Saturday, Dec 9 17:30–19:30	Deconvoluting clonal and cellular architecture in <i>IDH</i> -mutant acute myeloid leukemia	Maria Sirenko
	<b>2933</b> <a href="#">View</a>	Sunday, Dec 10 18:00–20:00	Single-cell proteomic analysis reveals menin inhibition-induced proteomic alterations in AML patients treated with revumenib	Mahesh Basyal



## ASH 2023

Follow us on X to keep up to date  
with the latest from the congress

**@AML\_Hub**

**#ASH23**

**View all @AML\_Hub tweets from #ASH23**



Brought to you by

